Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | LPL | P06858 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14251544 | 0.76 | IRAK4 (0.41) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL21929910 | 0.76 | CRHR1 (0.31) | — | |
| SCHEMBL21929819 | 0.74 | LPL (0.30) | LPLLIPG | |
| SCHEMBL30748768 | 0.73 | IRAK4 (0.36) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL18480146 | 0.72 | CYP4F2 (0.39) | IRAK4 | |
| SCHEMBL28664045 | 0.71 | FFAR1 (0.39) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL18985993 | 0.70 | FFAR1 (0.45) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL16728686 | 0.70 | IRAK4 (0.38) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL30551179 | 0.69 | IRAK4 (0.47) | IRAK4FFAR1LPLLIPG | |
| SCHEMBL31221824 | 0.69 | ADORA3 (0.38) | IRAK4FFAR1LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2024-06-11 | — | — | US | disclosed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2021-12-23 | — | — | US | disclosed |
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-08-03 | — | — | US | disclosed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102198-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CG | IRAK4 441/4885FFAR1 3157/4885LPL 2867/4885 |
| US-12006320-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | IRAK4 309/4885FFAR1 2276/4885LPL 2811/4885 |
| US-11078204-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CA | IRAK4 309/4885FFAR1 2276/4885LPL 2811/4885 |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CG | IRAK4 441/4885FFAR1 3157/4885LPL 2867/4885 |
| US-20210395258-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | IRAK4 309/4885FFAR1 2276/4885LPL 2811/4885 |
| US-20200148689-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CA | IRAK4 309/4885FFAR1 2276/4885LPL 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.